EMA und FDA sind uneins | PZ – Pharmazeutische Zeitung
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study - The Lancet Diabetes & Endocrinology
FDA Adds Ketoacidosis, UTI Warnings to Invokana & SGLT2 Inhibitors
Pharmaceuticals | Free Full-Text | The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study
Farxiga Gets FDA Greenlight for CKD | MedPage Today
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus - The Lancet Diabetes & Endocrinology
FDA Approves Diabetes Medication for Heart Failure - Diabetes Education Services
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
FDA rejects dapagliflozin as treatment add-on for type 1 diabetes - Diabetes
A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus - ScienceDirect
FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations | DAIC
Cureus | The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan
FDA Approves Expanded Indication for dapagliflozin in Type 2 Diabetes, Kidney Disease | dLife
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
FDA says no to Lilly, Boehringer's Jardiance in type 1 diabetes - PMLiVE
Despite Approvals in Europe and Japan, FDA Rejects AstraZeneca's Farxiga as Adjunct for Type 1 Diabetes | BioSpace
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
Reference ID: 4788803
Drugs in Perspective: Farxiga (dapagliflozin)
